Comparison of Safety and Efficacy Between the Robot-assisted System AVIAR (MX-02) Procedure and Conventional Manual Procedure in Patients Requiring Percutaneous Coronary Intervention

Not yet recruiting

• Conditions: Percutaneous Coronary Intervention

• Registration Number: NCT06735716
• Lead Sponsor: Asan Medical Center

Brief Summary

The objective of this study is to compare and evaluate the safety and efficacy of robot-assisted procedures using the positioning catheter control device 'AVIAR (MX-02)' versus conventional manual procedures in patients with Stable angina requiring percutaneous coronary intervention (PCI)

Detailed Description

A potential subject who meets the 'general inclusion/exclusion criteria' will be admitted before the procedure, undergo pre-procedure treatment according to the institution's standard procedures, and receive coronary angiography on the day of the procedure under local anesthesia. At this time, the investigator will review the 'coronary angiography inclusion/exclusion criteria', and only subjects who meet all the criteria will be enrolled in the clinical trial.

After the subject is assigned a registration number, the robot-assisted procedure group will undergo percutaneous coronary intervention (PCI) using the clinical trial medical device 'AVIAR (MX-02)', while the conventional manual procedure group will undergo percutaneous coronary intervention (PCI) according to the standard procedure.

After the procedure, the subjects will remain in a supine position for approximately 4 hours in the recovery room or hospital room to ensure absolute stability. During this time, the investigator will observe the puncture site for hemostasis and monitor for any adverse events. Within 2 days after the procedure or prior to discharge, the subjects will undergo safety assessments and evaluations for the occurrence of any adverse events or serious adverse events. Additionally, at the 1-month follow-up, all required follow-up tests will be completed, and if no adverse events have occurred or if any previously occurring adverse events have been resolved, the clinical trial for that particular subject will be concluded. However, if any adverse events remain unresolved and are deemed unrelated to the clinical trial by the investigator, the trial may be terminated for that subject. Please note that the above information is a general description of the procedure and criteria for the clinical trial involving percutaneous coronary intervention using the AVIAR (MX-02) device.

Study Timeline

• Status Verified: 2024-12
• Study First Submitted: 2024-12-09
• Study First Submitted QC: 2024-12-11
• Last Update Submitted: 2024-12-11
• Study First Posted: 2024-12-16
• Last Update Posted: 2024-12-16
• Study Start: 2025-01-15
• Primary Completion: 2025-12-31
• Study Completion: 2026-03-30

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

• * General Inclusion Criteria

  1. Adult women and men who are aged ≥19

  2. Those who are suspected of stable angina and need percutaneous coronary intervention

  3. Those who voluntarily decided to participate in this clinical trial and agreed in writing to the informed consent form

  4. Those who are willing to comply with the protocol.

     * Angiographic Inclusion Criteria

  5. If the target lesion is a single lesion.

  6. If the lesion to be treated by coronary angiography (target lesion) is a native coronary artery lesion that has not been previously treated.

  7. If the diameter of the lesioned vessel to be treated by coronary angiography (target vessel) is between 2.5 mm and 4.5 mm (by visual estimate).

  8. If diameter stenosis of the target vessel ≥50% (by visual estimate)

Exclusion Criteria

• * General Exclusion Criteria

  1. Those with a left ventricular ejection fraction (LVEF) ≤ 30%
  2. Those who have a history of hypersensitivity to contrast agents such as stainless steel, cobalt-chromium, etc.
  3. Those who cannot stop taking antithrombotic drugs (anticoagulants, antiplatelet drugs)
  4. Those diagnosed with thrombocytopenia, thrombocytosis, neutropenia, or leukopenia
  5. Those who have a history of bleeding diathesis or coagulopathy or who refuse transfusion
  6. Those with a history of stroke (CVA) or transient ischemic attack (TIA) within 4 weeks from the screening date
  7. .Those with a history of active peptic ulcer or upper gastrointestinal bleeding within 24 weeks from the screening date
  8. Those with ST-elevation myocardial infarction (STEMI) (for example, those who started myocardial infarction symptoms within 72 hours from the screening date)
  9. Those with a history of cardiogenic shock or cardiac arrest
  10. Those who underwent coronary artery bypass grafting (CABG)
  11. Those who underwent percutaneous coronary intervention (PCI) within 72 hours from the screening date
  12. Those who had a major adverse coronary event (MACE) or a serious adverse event (SAE) after receiving the percutaneous coronary intervention (PCI) within 4 weeks from the screening date
  13. Those who are scheduled to undergo percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) within 4 weeks from the end of this clinical trial
  14. Those diagnosed with renal failure or those who are not suitable for angiography due to severe renal dysfunction (creatine >2.0 mg/dL or eGFR (estimated glomerular filtration rate) <30 ml/min) within one week prior to the date of coronary angiography
  15. Pregnant and breastfeeding women
  16. Women of childbearing potential who plan to become pregnant during this clinical trial
  17. A woman* or spouse who is likely to be pregnant does not agree to use contraception in medically acceptable method of contraception** during the clinical trial
  18. Those who are currently participating in other clinical trials or have experience participating in other clinical trials within 12 weeks from the screening date.However, where at least one or more conditions are satisfied, it could be an exception according to an investigator's discretion

• Participated in the observational study expected no effect on the safety and/or effectiveness evaluation of this trial

• Screening failed before any interventional factor is involved-Participated in academic trials like strategic or medical device comparison 19. Other cases where the investigator determines that participation in a clinical trial is inappropriate ethically or because it may affect the study outcome.

  • Angiographic Exclusion Criteria

    1. Those who require manual or mechanical thrombectomy, rotational atherectomy, directional coronary atherectomy (DCA), etc. in addition to stent placement and balloon dilatation 2. When the two-stent technique is required for the side branch of the target bifurcation lesion.

    2. When the investigator determines that PCI is not suitable because the target lesion hasany of the following characteristics:

    ①he target lesion is a chronic total occlusion (CTO) or total occlusion

    ②An ostial lesion in location

    ③The target vessel has evidence of intraluminal thrombus

    ④Moderate or severe calcification at the target lesion or near the target lesion

    ⑤If PCI cannot be performed for other reasons 4. If the investigator determines that the subject is not suitable for robotic-assisted PCI due to clinical and anatomical reasons.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Clinical Success Criteria	48hours	If the residual stenosis rate of the lesion is less than 30% after completion of percutaneous coronary intervention using an investigational device If major adverse cardiovascular events (MACE)† have not occurred within 48 hours after the procedure or the time of discharge, whichever comes first
Technical Success Criteria	48hours	The stent (or balloon catheter) has successfully reached the target lesion without switching to manual manipulation.
Radiation exposure Patient	48hours	Patient Radiation exposure (Gy): The total procedure time is defined as the period from the insertion of the guidewire and guide catheter (introducer sheath) to their removal, during which the radiation exposure (DAP, Air Kerma) and fluoroscopy time are measured on the C-arm.
Radiation exposure Operator	48hours	Operator radiation (mSv):It is verified by the radiation exposure measured using the personal electronic dosimeter worn by the operator on the chest and the radiation exposure measured on the procedure table.

Secondary Outcome Measures

Name	Time	Method
TEAE	1month	Treatment emergent adverse event, TEAE
MACE	1month	Major Adverse Cardiovascular Events) occurring in the study subjects during the clinical trial period.

Trial Locations

Locations (2)

The Catholic University of Korea, Eunpyeong St. Mary's Hospital; 🇰🇷 Seoul, Korea, Republic of

Asan Medical Center; 🇰🇷 Seoul, Korea, Republic of